AZ Fizzles in Phase 3 Trial for Cancer Drug Selumetinib

AstraZeneca has revealed that its cancer drug candidate selumetinib fell short in a Phase 3 trial.

The company said the drug did not meet its primary endpoint of progression-free survival in patients when tested in combination with docetaxel chemotherapy.

AstraZeneca said it will present data from the study at a medical conference at some unspecified point in the future.